Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.
Lloyd P, Hong A, Furrer MA, Lee EWY, Dev HS, Coret MH, Adshead JM, Baldwin P, Knight R, Shamash J, Alifrangis C, Stoneham S, Mazhar D, Wong H, Warren A, Tran B, Lawrentschuk N, Neal DE, Thomas BC. Lloyd P, et al. Among authors: shamash j. World J Urol. 2022 Jan;40(1):119-126. doi: 10.1007/s00345-021-03832-0. Epub 2021 Oct 1. World J Urol. 2022. PMID: 34599350
A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA, Gabe R, Cafferty FH, Pollock P, White JD, Shamash J, Cullen MH, Stenning SP; TE23 Trial Management Group and Collaborators; National Cancer Research Institute Testis Cancer Clinical Studies Group. Huddart RA, et al. Among authors: shamash j. Eur Urol. 2015 Mar;67(3):534-43. doi: 10.1016/j.eururo.2014.06.034. Epub 2014 Jul 4. Eur Urol. 2015. PMID: 25001888 Free PMC article. Clinical Trial.
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W, Krell J, Chowdhury S, Harland SJ, Mazhar D, Harding V, Frampton AE, Wilson P, Berney D, Stebbing J, Shamash J. Badreldin W, et al. Among authors: shamash j. BJU Int. 2016 Mar;117(3):418-23. doi: 10.1111/bju.13004. Epub 2015 Jun 13. BJU Int. 2016. PMID: 25430674 Free article.
Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.' by Loriot and colleagues.
Alifrangis C, Wilson P, Shamash J. Alifrangis C, et al. Among authors: shamash j. Eur J Cancer. 2018 May;95:102-103. doi: 10.1016/j.ejca.2018.01.116. Epub 2018 Mar 31. Eur J Cancer. 2018. PMID: 29615282 No abstract available.
202 results